"The medication isn't working" is one of the most common things people say when they're not losing weight on a GLP-1. It's also, most of the time, the wrong conclusion. GLP-1 drugs have high response rates in clinical trials — but "working" requires the right dose, over enough time, without something else counteracting it. When weight loss is absent or stalled, there's almost always a specific cause. The goal is to find it.
The drug is probably working
True pharmacological non-response to semaglutide or tirzepatide exists but is genuinely uncommon. In SURMOUNT-1, 91% of patients on tirzepatide 15mg achieved at least 5% weight loss. In STEP 1, 86% of patients on semaglutide 2.4mg achieved the same. The small fraction of true non-responders may have genetic variants in GLP-1 receptor signaling or downstream pathways — this is an active area of research — but they are not the typical patient staring at an unchanged scale.
What's more common: weight loss is slower than expected, has plateaued, or the patient is comparing their week-eight results to someone else's six-month transformation. Slower-than-expected progress is not non-response. It usually points to a correctable variable.
Wrong dose, or too early
This is the most common reason weight loss is disappointing in the first several months — and the most straightforward to fix.
Most of the meaningful weight loss with semaglutide happens at the 1.7mg and 2.4mg doses, not at 0.5mg or 1.0mg. Most of the meaningful weight loss with tirzepatide happens at 10mg and 15mg, not at 2.5mg or 5mg. The dose escalation schedule exists to minimize side effects — it is not the dose at which the drug is doing its primary job.
Being at a starting or intermediate dose for three months and seeing modest results is expected. That's not the drug failing. That's the ramp. If your dose hasn't reached therapeutic range, the clinical trial comparison numbers aren't yet applicable to your situation.
Patients who escalate too slowly — because providers are conservative or because they tolerate the lower dose fine and don't push for escalation — often plateau at sub-therapeutic doses and conclude the medication doesn't work for them. The correct interpretation is that they haven't yet been on a dose adequate to evaluate the medication.
Definition(Therapeutic dose vs. starting dose)
Semaglutide starts at 0.25mg weekly and reaches the primary therapeutic dose of 2.4mg (for obesity) over approximately 16–20 weeks. Tirzepatide starts at 2.5mg and reaches 10–15mg over a similar period. The purpose of the gradual escalation is GI tolerability, not efficacy — the drug is titrating up to where it actually works. Weight loss comparisons to trial data are only valid once you've been at maximum tolerated dose for at least 8–12 weeks.
Thyroid dysfunction
Hypothyroidism slows metabolic rate, impairs thermogenesis, and significantly blunts weight loss response to any intervention — including GLP-1 therapy. The mechanism is straightforward: thyroid hormone is required for normal mitochondrial function and basal metabolic rate. Without adequate thyroid hormone, TDEE falls, and even aggressive caloric restriction or pharmaceutical appetite suppression fails to produce expected weight loss.
TSH is a mandatory check when weight loss is poor. Hypothyroidism is common — affecting roughly 5% of the adult US population with a large additional fraction subclinically affected — and frequently undiagnosed. Symptoms overlap with the fatigue and GI slowdown that GLP-1s can cause, which means hypothyroidism can masquerade as medication side effects.
GLP-1 drugs do not treat thyroid dysfunction and cannot compensate for it. A patient with uncontrolled hypothyroidism on semaglutide 2.4mg may see almost no weight loss regardless of dose. Optimizing thyroid status often restores weight loss response dramatically. This is the most impactful lab check for non-response.
Insulin resistance beyond what the drug addresses
GLP-1 drugs improve insulin sensitivity, but in patients with severe, multi-factorial insulin resistance — evidenced by very high fasting insulin levels, acanthosis nigricans (darkened skin at neck and armpits), or a history of significant metabolic syndrome — the drug's insulin-sensitizing effects may be insufficient as monotherapy.
In these patients, adding metformin or an SGLT-2 inhibitor (empagliflozin, dapagliflozin) alongside the GLP-1 can restore response. Metformin reduces hepatic glucose output and improves peripheral insulin sensitivity through AMPK activation — a different mechanism than the GLP-1 pathway. SGLT-2 inhibitors independently drive caloric loss through glucosuria (excreting glucose in urine) and have additive weight loss of 2–4kg on top of GLP-1 therapy.
The combination isn't about using more drugs — it's about targeting insulin resistance from multiple mechanistic angles when one isn't sufficient.
Under-eating and metabolic adaptation
This is counterintuitive but real: eating too little can stall weight loss on a GLP-1.
The mechanism is metabolic adaptation. When caloric intake drops below approximately 800–900 calories consistently, the body responds by reducing total daily energy expenditure — slowing basal metabolic rate, reducing NEAT (non-exercise activity thermogenesis, meaning unconscious movement like fidgeting and posture adjustment), and down-regulating thyroid conversion. This is an evolutionary conservation response, not a pathology.
GLP-1 drugs suppress appetite so aggressively that some patients end up eating 600–700 calories a day without feeling hungry. They believe this is maximizing weight loss. In fact, they've triggered the body's starvation defense mechanisms, and weight loss slows or stops even at very low intake.
The fix — eating more than feels intuitive — is also necessary for muscle preservation and micronutrient adequacy. The target should be at least 1,000–1,200 calories for most patients, with strong emphasis on protein to prevent lean mass loss during the deficit.
Warning(More restriction is not always more weight loss)
If you're consistently eating under 800 calories and weight loss has stalled, the problem is likely not insufficient restriction — it's metabolic adaptation. The body reads extreme restriction as a survival threat and compensates by reducing energy expenditure. Increasing intake to 1,000–1,200 calories, particularly from protein, often restarts weight loss by removing the starvation signal. This is one of the more counterintuitive interventions in obesity medicine.
Medications causing weight gain
Several commonly prescribed medications cause weight gain by mechanisms strong enough to partially or fully neutralize GLP-1-mediated weight loss:
Antipsychotics: Olanzapine and quetiapine are the most weight-promoting. They block H1 histamine receptors and muscarinic receptors in the hypothalamus, directly increasing appetite and reducing satiety signals. Weight gain of 5–10kg in the first year is common. GLP-1 drugs can partially offset this, but the pharmacological weight-promoting effect can be too strong to overcome.
Antidepressants: Mirtazapine (strong H1 antagonism) and paroxetine (serotonergic mechanisms) are the highest-risk agents in their class. SSRIs as a class have a smaller effect. The combination of antidepressant-driven weight gain and GLP-1-mediated weight loss creates a pharmacological tug-of-war.
Steroids: Chronic corticosteroid use (prednisone, dexamethasone) causes weight gain through multiple pathways — central fat redistribution, increased appetite, impaired insulin sensitivity. This is not contraindicated with GLP-1s, but the steroid effect competes directly.
Insulin and sulfonylureas: Both drive weight gain through insulin-mediated fat storage and hypoglycemia-driven compensatory eating. Combining with GLP-1s often allows dose reductions in these agents, which helps.
Antihistamines: Long-term use of first-generation antihistamines (diphenhydramine, hydroxyzine) causes weight gain through H1 antagonism — the same mechanism as olanzapine, though weaker.
A comprehensive medication review is part of the workup for non-response. Sometimes a medication can be switched to a more weight-neutral alternative.
Sleep and cortisol
Chronic poor sleep independently stalls weight loss, and the mechanism is strong enough to counter GLP-1 effects in susceptible patients.
Sleep deprivation raises ghrelin (appetite stimulant) and suppresses leptin (satiety hormone) — producing the same hunger-promoting hormonal environment that GLP-1s are trying to correct. More relevant to stalled weight loss: poor sleep elevates cortisol. Chronically elevated cortisol promotes visceral fat storage, impairs lipolysis, induces insulin resistance, and reduces muscle protein synthesis. These effects work in the opposite direction of everything a GLP-1 is doing.
Patients who are sleeping under six hours per night, have untreated sleep apnea, or have chronically dysregulated cortisol (from shift work, stress, or HPA axis dysfunction) may see limited weight loss response despite adequate medication dose and appropriate diet. Sleep optimization — including sleep apnea treatment, which itself improves GLP-1 response through independent metabolic pathways — is part of the non-response workup.
What to do
A systematic approach to non-response covers four variables:
-
Confirm the dose is adequate. Are you at or near maximum therapeutic dose? If not, work with your provider on escalation timeline before concluding the medication isn't working.
-
Get baseline labs. TSH (thyroid), fasting insulin, comprehensive metabolic panel, vitamin D, and ferritin at minimum. These catch hypothyroidism, insulin resistance severity, and nutrient deficiencies that explain non-response.
-
Review all medications. List every prescription, OTC medication, and supplement. Identify anything with known weight-promoting effects and discuss alternatives with your provider.
-
Audit intake and sleep. Track protein specifically — most patients under-eat protein before they under-eat anything else. Quantify sleep hours and quality. These two variables, corrected, restore weight loss response in a meaningful fraction of stalled patients.
User Sentiment
Non-response frustration is among the most common topics in GLP-1 communities — but the conversations that follow are often genuinely useful.
Example(What the community says)
The most common post format: "I've been on Ozempic for four months and only lost 6 pounds. I feel like it's not working." The replies from experienced members consistently run through a checklist — what dose are you on, did you get thyroid labs, what are you eating, are you sleeping. In a significant fraction of these threads, someone identifies the specific variable: the poster is still on 0.5mg, or they discover they're eating 700 calories a day and didn't realize that was a problem, or a member asks about their antidepressant and it's mirtazapine. The community-level troubleshooting is remarkably consistent with clinical guidance — and people who follow through on the checklist frequently come back to report they figured it out.
Who It's For
This post is for anyone on a GLP-1 drug who is disappointed by their weight loss results — whether that means no loss, very slow progress, or a plateau after initial loss. It's also for clinicians who want a structured framework for non-response workup.
The most important thing to take away: GLP-1 non-response is almost always explainable. The explanations are almost always findable with a systematic approach. And most of them are correctable.
Summary(The short version)
GLP-1 drugs have response rates above 85% at adequate doses in clinical trials. When weight loss is absent or stalled, the most common reasons are: inadequate dose (most weight loss happens at maximum therapeutic dose, not during the ramp); hypothyroidism (mandatory TSH check — this single variable explains many cases of non-response); severe insulin resistance (may require adding metformin or an SGLT-2 inhibitor); metabolic adaptation from eating too little (consistently under 800–900 calories triggers compensatory metabolic slowing); medications causing weight gain (antipsychotics, mirtazapine, steroids, sulfonylureas); and chronic sleep deprivation (ghrelin elevation and cortisol-mediated fat storage counter GLP-1 effects). The workup: confirm dose adequacy, get TSH + fasting insulin + metabolic panel, review all medications, and audit protein intake and sleep quality.